Clinical Trial Update: TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function. [Phase 1]

View source ↗

Summary

Phase 1 PK and safety study assessing rilpivirine (TMC278) in HIV patients with mild-to-moderate hepatic impairment; focuses on pharmacokinetics and tolerabilit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• rilpivirine (rilpivirine)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV, AIDS | Phase 1 | Status: COMPLETED